IBCL-301 Primary Extranodal Marginal Zone B-Cell Lymphoma Located in the Lower Eyelid Case Treated With Rituximab

Abstract

The majority of lymphoma cases are accompanied by painless enlargement of several cervical lymph nodes. However, its primary site may be also extranodal and unusual in some cases. Sharing an unusual case report of primary lower eyelid extranodal marginal zone B-cell Lymphoma treated with rituximab. A case report. In January 2021, a 53-year-old woman was admitted to our clinic with a subcutaneous change in her lower eyelid. The patient had a history of hypertension and had undergone IVF several years ago. There was a positive family history of cancer. There were no palpable lymph nodes in the periphery in physical examination. The hemogram and laboratory examinations were normal, as was the abdominal echo examination. An MRI scan of the cranium/orbits revealed the presence of a mass with a size of 15×8×13mm in the canthal angle/lower right cover OD, with no signs of intra-bulbar infiltration. A mass biopsy was performed, and the HP diagnosis revealed an extranodal marginal zone B-cell lymphoma (CD20+) (Bcl2+) (CD138+). Once the nature of the disease and the location of the mass had been determined, treatment with Rituximab 375mg/m2 every 28 days was planned. After 10 cycles of treatment, a PET-CT scan was performed, and a small region with low metabolic activity SUV max 3.0 was detected retrobulbar laterally on the right side. A cranial MRI scan revealed no evidence of recurrence or other pathological signs. The laboratory, abdominal, and neck echo exams were all normal. The patient's condition remains stable despite receiving rituximab 375 mg/m2 every two months, with no signs of disease and a normal MRI scan. The prognosis of this type of tumor is difficult to predict because the long-term response to the primary treatment must be closely monitored.